Physical Activity to Prevent and Treat Hyperglycemia From a Mistimed Bolus Insulin Dose
Recruiting now NCT06686329
Run by Jane Yardley · for 18 to 24 · All sexes
What this study is about
People living with type 1 diabetes (PwT1D) are recommended to administer insulin 10-15 minutes before meal consumption (pre-bolus), to account for the delay in the glucose lowering action associated with subcutaneously administered insulin. Due to the demands of day-to-day life, pre-bolusing is not always possible or may be forgotten. With continuous glucose monitors (CGMs), PwT1D may be alerted to this missed insulin dose by a CGM alert, including rapidly rising glucose (change \>2.5mmol/L/15min) or hyperglycemia (\>10.0 mmol/L), and deliver a mistimed (post-prandial) dose in response to CGM alert. This study was designed to determine the effect of combining a post-prandial/mistimed insulin dose with 15 minutes of brisk walking. It is expected that walking will help to minimize or prevent hyperglycemia after a mistimed bolus insulin dose, as well as blunt the rise in glucose following a mistimed insulin dose.
Who can join (things the study team will check)
✅ You may be able to join if…
- Adults aged 18-24 years
- Type 1 diabetes diagnostic for at least two years
- Estimated glycated hemoglobin or glucose management indicator obtained from the past 30 days of CGM data of < 9.9%
- Use a Dexcom G7 CGM in routine care
🚫 You may not be able to join if…
- Changes in insulin management strategy within the past 2 months
- Diagnosis of gastroparesis
- Having a condition that could render exercise harmful
- Intolerance to gluten and lactose
- Having significant renal disease (e.g., eGRF < 30 ml/min)
- Inability to provide informed consent due to cognitive deficit
- Currently taking other medications (other than insulin) that may alter glucose metabolism (e.g., non-insulin antihyperglycemic drugs such as sglt2-inhibitors, corticosteroids), unless dosages thereof have been stable for more than three months
- For women, being pregnant or breastfeeding
Where this trial is running
- Institut de recherches cliniques de Montréal, Montreal, Quebec, Canada
Who to contact
Corinne Suppère, MSc · 514-987-5597 · corinne.suppere@ircm.qc.ca
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT06686329.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.